EL7.AI
StocksMedium•30 July 2026•
1 min read

Agios Pharmaceuticals Surges on Revenue Beat and Price Target Upgrade

Key Facts

1H.C. Wainwright raised its price target for Agios Pharmaceuticals to $55.00, suggesting a potential 67.05% upside.
2The company reported Q2 2026 revenues of $44.75 million, beating the Zacks Consensus Estimate by 97.29%.
3Loss per share was $1.69, which was better than the expected loss of $1.86 per share.

Reflecting growing optimism in the biotech sector, Agios Pharmaceuticals reported strong financial results for the second quarter of 2026. The company achieved revenues of $44.75 million, significantly beating analyst estimates by 97.29%, while reporting a loss per share of $1.69, which was narrower than the anticipated $1.86 loss. This robust performance was primarily driven by the successful U.S. launch of AQVESME for thalassemia and the strong performance of mitapivat.

According to reports, H.C. Wainwright raised its price target for Agios Pharmaceuticals to $55.00, suggesting a potential upside of 67.05%. This positive valuation is supported by the company's solid financial position, holding $964.80 million in cash and equivalents, alongside progress in its sickle cell disease drug pipeline which has received FDA Priority Review.

Investors should watch for upcoming drug approval milestones as catalysts, while economic calendar data shows stability in macro indicators such as U.S. Durable Goods Orders, which grew by 0.3% on July 27.